首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1626595

全球流式细胞仪市场规模：依产品、技术、应用、最终用户、区域覆盖和预测

Global Flow Cytometry Market Size By Product, By Technology, By Application, By End-User, By Geographic Scope And Forecast

出版日期: 2024年11月13日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

流式细胞仪市场规模及预测

2024年流式细胞仪市场规模价值 46.8亿美元，预计到2031年将达到 80.6亿美元，2024年至2031年的年复合成长率为 7.75%。

流式细胞仪是一种先进的实验室技术，可以以极高的精确度和速度分析单一细胞。

这项先进的技术利用流式细胞仪。流式细胞仪是一种专门的仪器，可以测量穿过雷射光束的细胞的物理和化学特性。

流式细胞仪每秒可快速分析数千个细胞，实现高效、全面的资料收集。

此技术能够侦测到细胞特性的细微变化，确保分析的准确性和精确性。

流式细胞仪可以测量多种细胞特征，包括大小、形状、粒度和表面标誌表达。

此技术可以同时测量每个细胞的多个参数，全面了解细胞特性。

流式细胞仪彻底改变了细胞生物学，并已成为研究、诊断和药物开发的重要工具。

全球流式细胞仪市场动态

影响全球流式细胞仪市场的关键市场动态是：

主要市场驱动因子

慢性病发生率不断上升：慢性病的发生率不断上升，推动了流式细胞仪的需求。该技术在各种疾病的诊断和监测中发挥着重要作用。根据世界卫生组织（WHO）的资料，到2023年，慢性病将占全球死亡人数的71%。

癌症研究中的应用日益广泛：流式细胞仪在癌症研究和诊断中的应用迅速扩大。流式细胞仪可以详细分析肿瘤细胞和免疫反应。这项技术将有助于开发针对性治疗方法和监测治疗结果。例如，2024年3月15日，Beckman Coulter宣布了专为癌症免疫治疗研究设计的新型流式细胞仪平台。

在药物研发中的应用日益广泛：製药公司日益在药物研发中使用流式细胞仪。该技术对于高通量筛选和先导化合物最佳化非常有用。它们在评估药物功效和毒性方面也发挥着重要作用。2024年1月，美国FDA报告40%的新药核准包括流式细胞仪资料。

促进HIV/AIDS监测的进步：流式细胞仪对于诊断和监测HIV/AIDS非常重要。流式细胞仪可以准确测量 CD4+ T 细胞计数，这对于疾病管理非常重要。技术的进步使得这些测试更容易获得且更便宜。联合国爱滋病规划署2023年 12月报告指出，由于流式细胞仪等检测方法的改进，84%的爱滋病毒感染者了解自己的感染状况。

主要问题

高成本阻碍了广泛采用：流式细胞仪设备需要大量的初始投资，这可能会阻碍其在预算有限的小型研究机构和实验室中的采用。这种经济障碍可能会限制人们获得这种宝贵的技术，特别是在发展中地区。

操作复杂性和资料分析挑战：流式细胞仪的有效操作需要专门的训练和专业知识。此外，复杂的资料分析和解释过程需要专门的软体和生物资讯技能。这些挑战可能会限制研究人员和临床医生使用流式细胞仪的效率和可及性。

影响准确性的技术限制：儘管技术进步，流式细胞仪技术在灵敏度、分辨率和分析稀有细胞群的能力方面仍然存在限制。克服这些技术障碍对于提高流式细胞仪的准确性和可靠性非常重要。

与替代技术的竞争限制了市场成长：流式细胞仪与其他细胞分析技术竞争，例如质谱流式细胞仪和成像流式细胞仪。这些替代技术可能提供某些优势，例如更高的灵敏度和即时视觉化功能。这样的竞争可能会限制传统流式细胞仪的市场成长。

主要趋势

干细胞研究的需求不断成长：不断扩大的干细胞研究领域在很大程度上依赖流式细胞仪。流式细胞仪可以精确识别和分离干细胞群。这项技术对于再生医学治疗的发展非常重要。例如，2024年4月，Thermo Fischer Scientific推出了针对干细胞分析最佳化的新型流式细胞仪。

在免疫学研究中的用途不断扩大：流式细胞仪的详细分析在免疫学研究中变得越来越重要。这对于了解免疫反应和开发免疫疗法非常重要。美国国立卫生研究院报告指出，使用流式细胞仪的免疫学研究经费将在 23 财政年度增加 30%。

微生物学中越来越多的应用：流式细胞仪在微生物学和传染病研究中找到了新的用途。流式细胞仪可以快速检测和鑑定微生物。这项技术对于食品安全、水质和环境监测非常重要。例如，2024年 2月，BD Biosciences 推出了一种新的流式细胞仪检测方法，用于快速检测抗生素抗药性细菌。

促进血液学诊断的进步：流式细胞仪继续彻底改变血液学诊断。这项技术对于诊断和监测血液疾病非常重要。美国血液学会于2023年 11月报告指出，目前85%的血液学实验室使用流式细胞仪作为主要诊断工具。

Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases drives demand for flow cytometry. This technology plays a crucial role in diagnosing and monitoring various conditions. According to the World Health Organization, chronic diseases accounted for 71% of global deaths in 2023.

Growing Applications in Cancer Research: Flow cytometry's use in cancer research and diagnostics is expanding rapidly. It enables detailed analysis of tumor cells and immune responses. This technology aids in developing targeted therapies and monitoring treatment efficacy. For instance, in March 15, 2024, Beckman Coulter announced a new flow cytometry platform specifically designed for cancer immunotherapy research.

Increasing Adoption in Drug Discovery: Pharmaceutical companies are increasingly using flow cytometry in drug discovery. The technology helps in high-throughput screening and lead optimization. It also plays a vital role in assessing drug efficacy and toxicity. The U.S. FDA reported in January 2024 that 40% of new drug approvals involved flow cytometry data in their submissions.

Fueling Advancements in HIV/AIDS Monitoring: Flow cytometry remains essential for HIV/AIDS diagnosis and monitoring. It accurately measures CD4+ T-cell counts, crucial for disease management. Technological improvements are making these tests more accessible and affordable. UNAIDS reported in December 2023 that 84% of people living with HIV know their status, largely due to improved testing methods including flow cytometry.

Key Challenges:

High Cost Hindering the Widespread Adoption: The substantial initial investment required for flow cytometry equipment can hinder its adoption by smaller research institutions or laboratories with limited budgets. This financial barrier may restrict access to this valuable technology, particularly in developing regions.

Operational Complexity and Data Analysis Challenges: Operating flow cytometry equipment effectively demands specialized training and expertise. Additionally, the intricate process of data analysis and interpretation necessitates specialized software and bioinformatics skills. These challenges can potentially limit the efficiency and accessibility of flow cytometry for researchers and clinicians.

Technological Limitations Affecting the Accuracy: Despite advancements, flow cytometry technology still faces limitations in terms of sensitivity, resolution, and the ability to analyze rare cell populations. Overcoming these technological hurdles is imperative for enhancing the accuracy and reliability of flow cytometry.

Competition from Alternative Technologies Restricting the Market Growth: Flow cytometry competes with other cell analysis techniques, including mass cytometry and imaging flow cytometry. These alternative technologies may offer certain advantages, such as higher sensitivity or real-time visualization capabilities. Such competition can potentially limit the market growth for traditional flow cytometry.

Key Trends

Rising Demand in Stem Cell Research: The expanding field of stem cell research heavily relies on flow cytometry. It enables precise identification and isolation of stem cell populations. This technology is crucial for developing regenerative medicine therapies. For instance, in April 2024, Thermo Fisher Scientific launched a new flow cytometer specifically optimized for stem cell analysis.

Growing Use in Immunology Studies: Immunology research increasingly depends on flow cytometry for detailed analysis. This is crucial for understanding immune responses and developing immunotherapies. The National Institutes of Health reported a 30% increase in immunology research grants utilizing flow cytometry in fiscal year 2023.

Increasing Applications in Microbiology: Flow cytometry is finding new applications in microbiology and infectious disease research. It enables rapid detection and characterization of microorganisms. This technology is crucial for food safety, water quality, and environmental monitoring. For instance, in February 2024, BD Biosciences introduced a new flow cytometry assay for rapid detection of antibiotic-resistant bacteria.

Fueling Advancements in Hematology Diagnostics: Flow cytometry continues to revolutionize hematology diagnostics. This technology is crucial for diagnosing and monitoring blood disorders. The American Society of Hematology reported in November 2023 that 85% of hematology laboratories now use flow cytometry as a primary diagnostic tool.

Global Flow Cytometry Market Regional Analysis

Here is a more detailed regional analysis of the global flow cytometry market:

North America

North America has established itself as the dominating region in the global flow cytometry market, driven by substantial investments in research and development, advanced healthcare infrastructure, and a high prevalence of chronic diseases.

The region boasts a large number of academic research institutions and pharmaceutical companies that extensively utilize flow cytometry in their studies and drug development processes.

This widespread adoption is further supported by favorable reimbursement policies and government initiatives promoting advanced diagnostic technologies.

According to the National Institutes of Health (NIH), funding for research projects involving flow cytometry increased by 15% in fiscal year 2023 compared to the previous year.

The market leadership of North America is also attributed to the presence of major flow cytometry manufacturers and continuous technological advancements in the field.

These companies are constantly innovating to improve the speed, accuracy, and versatility of flow cytometry instruments and reagents.

The region's strong focus on personalized medicine and immunotherapy research further fuels the demand for advanced flow cytometry solutions.

for instance, in June 1, 2024, Becton, Dickinson and Company (BD) announced the launch of its next-generation flow cytometer, which offers enhanced sensitivity and faster processing times, further solidifying North America's position in the global market.

Asia Pacific

The Asia Pacific region is projected to experience a rapid CAGR growth during the forecast period, driven by increasing healthcare expenditure and rising awareness about advanced diagnostic technologies.

Rapid economic development in countries like China and India is leading to improved healthcare infrastructure and greater adoption of sophisticated medical equipment.

The region's large population base and growing incidence of chronic diseases create a vast potential market for flow cytometry applications.

According to China's National Bureau of Statistics, healthcare spending in the country increased by 12.5% in 2023, reaching 7.8 trillion yuan (approximately $1.2 trillion USD).

Government initiatives to promote biotechnology research and development are further fueling the expansion of the flow cytometry market in Asia Pacific.

Many countries in the region are investing heavily in life sciences research and establishing state-of-the-art research facilities. This trend is attracting global pharmaceutical and biotechnology companies to set up research centers in the region.

For instance, in April 15, 2024, Sysmex Corporation, a leading Japanese flow cytometry manufacturer, announced the opening of a new R&D center in Singapore, focusing on developing novel flow cytometry applications for cancer diagnostics and immunotherapy research.

Global Flow Cytometry Market: Segmentation Analysis

The Global Flow Cytometry Market is segmented based on By Product, By Technology, By Application, By End-User, and Geography.

Flow Cytometry Market, By Product

Instruments
Cell Analyzers
Cell Sorters
Reagents & Consumables
Software
Accessories
Services

Based on Product, the Global Flow Cytometry Market is bifurcated into Instrument, Reagents & Consumables, Software, Accessories, Services. The instrument segment dominating the global flow cytometry market. This is due to increased penetration brought about by advancements in technology. However, the software segment is growing at a rapid CAGR within the global flow cytometry market. Software is essential for controlling and collecting data from cytometers, analysing data, and providing statistical insights.

Flow Cytometry Market, By Technology

Cell-based
Bead-based

Based on Technology, the Global Flow Cytometry Market is bifurcated into Cell-based, Bead-based. The cell-based segment is estimated to dominate the global flow cytometry market during the forecast period. The drug development, cell-based assays are employed to evaluate cell physiological properties and analyze the data gathered. However, the bead-based segment is growing at a rapid CAGR within the global flow cytometry market. These tests, which use sandwich or indirect immunoassay formats, are made especially to measure the number of antibodies present in biological fluids.

Flow Cytometry Market, By Application

Research
Pharmaceutical
Drug Discovery
Stem Cell
In Vitro Toxicity
Apoptosis
Cell Sorting
Cell Cycle Analysis
Immunology
Cell Viability
Others
Industrial
Clinical
Cancer
Organ Transplantation
Immunodeficiency
Hematology
Autoimmune Disorders

Based on Application, the Global Flow Cytometry Market is bifurcated into Research, Industrial, Clinical. The clinical segment is estimated to dominate the global flow cytometry market during the forecast period. It is anticipated that the biotechnology and pharmaceutical industries' growing R&D expenditures will provide a conducive atmosphere for market growth. However, the industrial segment is growing at a rapid CAGR within the global flow cytometry market, because of its growing use in fields including plant tissue culture, tissue culturing, microbiology, and the food sector.

Flow Cytometry Market, By End-User

Commercial Organizations
Biotechnology Companies
Pharmaceutical Companies
CROs
Hospitals
Academic Institutes
Clinical Testing Labs

Based on End-User, the Global Flow Cytometry Market is bifurcated into Commercial Organizations, Hospitals, Academic Institutes, Clinical Testing Labs. The academic institutes segment is dominating the global flow cytometry market. Numerous academic disciplines, including molecular biology, immunology, pathology, plant biology, and marine biology, use the technology. However, the clinical testing labs segment is rapidly growing, because target diseases like cancer are becoming more and more expensive to diagnose.

Flow Cytometry Market, By Geography

North America
Europe
Asia Pacific
Rest of the world

Based on Geography, the Global Flow Cytometry Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region has established itself as the dominating region in the global flow cytometry market, driven by substantial investments in research and development, advanced healthcare infrastructure, and a high prevalence of chronic diseases. However, the Asia Pacific region is projected to experience a rapid CAGR growth during the forecast period, driven by increasing healthcare expenditure and rising awareness about advanced diagnostic technologies.

Key Players

The "Global Flow Cytometry Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Siemens Healthcare GmbH, NextStep Solutions, McKesson Corporation, NextGen Healthcare, Genpact Limited, Athena Healthcare, Boston Consulting Group, Change Healthcare, Baker Tilly, USA, LLC, ForeSee Medical, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Flow Cytometry Market Key Developments

In March 2024, the FDA granted Beckman Coulter Life Sciences 510(k) permission to market the DxFLEX Clinical Flow Cytometer in the United States. Thanks to this development, labs may now do high-complexity flow cytometry testing more easily and affordably.
In January 2024, to promote technical innovation and expedite scientific discoveries, Cytek Biosciences, Inc. partnered with Pompeu Fabra University (UPF) and the Centre for Genomic Regulation (CRG). The cooperation opens the door for growth into new applications and highlights the important influence of Cytek's spectral flow cytometry technology.

1 INTRODUCTION OF GLOBAL FLOW CYTOMETRY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL FLOW CYTOMETRY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL FLOW CYTOMETRY MARKET, BY TECHNOLOGY

5.1 Overview
5.2 Cell-Based Flow Cytometry
5.3 Bead-Based Flow Cytometry

6 GLOBAL FLOW CYTOMETRY MARKET, BY PRODUCT

6.1 Overview
6.2 Instruments
- 6.2.1 Cell Analyzer
- 6.2.2 Cell Sorter
6.3 Reagents and Consumables
6.4 Services
6.5 Software
6.6 Accessories

7 GLOBAL FLOW CYTOMETRY MARKET, BY APPLICATION

7.1 Overview
7.2 Industrial Applications
7.3 Clinical Applications
- 7.3.1 Cancer
- 7.3.2 Hematology
- 7.3.3 Immunodeficiency Diseases
7.4 Research Applications
- 7.4.1 Pharmaceuticals and Biotechnology
- 7.4.2 Immunology
- 7.4.3 Cell Sorting

8 GLOBAL FLOW CYTOMETRY MARKET, BY END-USER

8.1 Overview
8.2 Hospitals and Diagnostic Laboratories
8.3 Biotechnology and Biopharmaceutical Companies
8.4 Research Laboratories and Institutes

9 GLOBAL FLOW CYTOMETRY MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL FLOW CYTOMETRY MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Biomerieux S.A
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Cytonome St
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Apogee Flow Systems
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Agilent Technologies
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Luminex
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Miltenyi Biotec
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Thermo Fisher Scientific
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Becton
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Dickinson and Company
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Merck KGaA
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments